ClinicalTrials.gg
CompletedNCT07025577Updated Sep 10, 2025

A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions

A Phase 1 interventional study of Immunoglobulin G in Healthy Participants, sponsored by Genentech, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will evaluate the safety and tolerability of SC administration of IgG in healthy participants.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) 18 to 36 kilograms per meter square (kg/m\^2), inclusive
  • For females of : agreement to remain abstinent (refrain from heterosexual intercourse) or use adequate during IgG administration and for 28 days after completion of IgG administration
  • For males: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 28 days after the last study drug administration
  • Positive (HIV) test
  • Positive surface antigen or hepatitis B core antibody test
  • Positive virus antibody test
  • Regular alcohol consumption of >8 drinks/week for females or >12 drinks/week for males
  • Poor peripheral venous access
  • Major surgical procedure within 28 days prior to initiation of study treatment or anticipation of need for a major surgical procedure during the study
  • Known to IgG or any of its components or to products made with IgG
  • History or presence of skin rash or other skin disorders
  • Inability to sense pain (e.g., peripheral neuropathy) or have a history of or have been diagnosed with a chronic pain syndrome
  • Infection or inflammation of the designated injection site (abdomen)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Sequence 1

    Participants will receive SC administrations of IgG into the abdominal region starting with Treatment B, followed by Treatment A.

    Drug: Immunoglobulin G

  • Experimental
    Sequence 2

    Participants will receive SC administrations of IgG into the abdominal region starting with Treatment A, followed by Treatment C.

    Drug: Immunoglobulin G

  • Experimental
    Sequence 3

    Participants will receive SC administrations of IgG into the abdominal region starting with Treatment D, followed by Treatment C.

    Drug: Immunoglobulin G

  • Experimental
    Sequence 4

    Participants will receive SC administrations of IgG into the abdominal region starting with Treatment B, followed by Treatment D.

    Drug: Immunoglobulin G

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Injection Site Tolerability Score on a Visual Analogue Scale (VAS)

    Time frame: Up to Day 4

  2. Mean Change From Baseline in Injection Site Tolerability Score on VAS

    Time frame: Baseline, Up to Day 4

  3. Percentage of Participants Experiencing Greater Than Mild Pain

    Time frame: Up to Day 4

  4. Percentage of Participants in Each VDS Category on the VDS Scale

    Time frame: Up to Day 4

  5. Percentage of Participants with Local Injection Site Reaction Using Local Injection-site Symptom Assessment (LISSA)

    Time frame: Up to Day 7

  6. Participant's Tolerability to Injection as Assessed by Tolerability Questionnaire

    Time frame: Up to Day 4

  7. Number of Participants with Visual Injection Site Tolerability as assessed using LISSA

    Time frame: Up to Day 4

  8. Number of Participants with Fluid Leakage

    Time frame: Up to Day 4

07

Study locations

3 sites
  • Daytona Beach Clinical Rsch Unit
    Daytona Beach, Florida 32117, United States
  • Fortrea Clinical Research Unit - Dallas
    Dallas, Texas 75247-4989, United States
  • Fortrea Clinical Research Unit Inc. - Madison
    Madison, Wisconsin 53704-2526, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2025 to primary completion in Aug 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2025
First posted
Jun 17, 2025
StartActual
Jun 2, 2025
Primary completionActual
Aug 8, 2025
CompletionActual
Sep 3, 2025
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07025577
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Jun 17, 2025
Start date
Jun 2, 2025
Primary completion
Aug 8, 2025
Completion
Sep 3, 2025
Last update
Sep 10, 2025

Study contacts

Clinical Trials
study director · Genentech, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulin G

Start the discussion